

# Now available Prpms-PIRFENIDONE

Anti-fibrotic / Anti-inflammatory Agent

A generic equivalent  
to ESBRIET®<sup>1</sup>



Demonstrated bioequivalent  
to ESBRIET®<sup>1</sup>



Same efficacy and safety  
as the brand<sup>2,3</sup>



At a  
lower price<sup>4</sup>



Financial assistance  
available



PRODUCT NAME	STRENGTH	FORMAT	DIN	PMS CODE	VISUAL COMPARISON <sup>4</sup>	
					Prpms-PIRFENIDONE	PrESBRIET® <sup>1</sup>
Prpms-PIRFENIDONE	267 mg	Bottle of 21 tablets Bottle of 270 tablets	02531526	5760629761 5760629762		
Prpms-PIRFENIDONE	801 mg	Bottle of 90 tablets	02531534	5760629763		

pms-PIRFENIDONE (pirfenidone) is indicated for treatment of idiopathic pulmonary fibrosis (IPF) in adults.<sup>2</sup>


Treatment with pms-PIRFENIDONE should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of IPF.



# Pr<sup>®</sup>pms-PIRFENIDONE

## Comparative Bioavailability Study of pms-PIRFENIDONE vs. ESBRIET<sup>®1</sup>

Linear profile of the mean plasma concentration-time (n = 62)



Double-blind, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, two-way crossover oral bioequivalence study comparing pms-PIRFENIDONE Tablets, 801 mg (Pharmascience Inc.) to ESBRIET<sup>®</sup> Tablets, 801 mg (Hoffmann-La Roche Limited) conducted in 62 in healthy, adult Asian Indian male subjects under fed conditions. The results from 62 subjects were available.\*

Consult the product monograph at [https://pdf.hres.ca/dpd\\_pm/00067682.PDF](https://pdf.hres.ca/dpd_pm/00067682.PDF) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-888-550-6060.

CI= confidence interval

\* Data on file. Pharmascience Inc.

1. ESBRIET<sup>®</sup> is a registered trademark of F. Hoffmann-La Roche AG.

2. Pr<sup>®</sup>pms-PIRFENIDONE (pirfenidone tablets) Product Monograph. Pharmascience Inc., September 13, 2022.

3. Pr<sup>®</sup>ESBRIET<sup>®</sup> (pirfenidone tablets) Product Monograph. Hoffmann-La Roche Limited., August 05, 2021.

4. No comparative clinical benefit implied.

5. Restrictions may apply.

In the province of Quebec, Bill 92 amended the *Act Respecting Prescription Drug* and prohibits manufacturers and wholesalers from reimbursing all or part of the price of a listed drug, provided some exceptions. YOUR PATIENT SUPPORT PROGRAM 'ALLY' & DESIGN<sup>®</sup> is a registered trademark owned by Finchley Research & Development Inc., used under licence by Pharmascience Inc.



## The Ally Patient Support Program

The Ally Program is dedicated to supporting you and your patients. Ally offers financial assistance similar to that of the brand.



### FINANCIAL ASSISTANCE<sup>5</sup>

**Support** for access to treatment when starting on pms-PIRFENIDONE for eligible patients. Electronic coverage via the new online portal is efficient and speeds up the payment process.

For more information, please consult: <https://myrx.care/en/ally>

## Together, let's support local businesses!

Choosing Pharmascience is choosing local, and contributing to the Canadian economy. Pharmascience employs nearly 1,500 people across the country.

Customer Service: 1-800-340-9735  
Medical Information: 1-888-550-6060  
[www.pharmascience.com](http://www.pharmascience.com)

